Table 2 Subgroup analyses for overall response at day 10 after treatment
|  | MTX cohort (Group A), %(95% CI) | Control cohort (Group B), %(95% CI) | P value |
|---|---|---|---|
Diagnosis | |||
 AML/MDS | 97.7(88.2- 99.6) | 79.6 (67.1- 88.2) | 0.011 |
 ALL or others | 97.0 (85.0- 99.4) | 84.0 (65.3- 93.6) | 0.075 |
Patient age | |||
  < 35 | 97.5 (87.1- 99.5) | 80.4 (65.9- 89.7) | 0.029 |
  ≥ 35 | 97.3 (86.5- 99.5) | 81.6 (66.5- 90.7) | 0.028 |
Patient gender | |||
 Male | 100 (91.6- 100) | 83.3 (69.3- 91.6) | 0.012 |
 Female | 94.4 (81.8- 98.4) | 78.3 (62.8- 88.6) | 0.047 |
MAGIC criteria grade | |||
 I-II | 100(95.0- 100) | 85.9 (75.9- 92.1) | 0.001 |
 III-IV | 50.0 (9.1- 90.8) | 37.5 (10.2- 74.1) | 0.57 |
GVHD risk category | |||
 Standard | 100 (95.1- 100) | 86.1 (76.2- 92.2) | 0.001 |
 High | 33.3 (1.7- 87.4) | 28.5 (5.1- 69.7) | 0.70 |
GVHD organ involvement | |||
 Skin | 97.1(90.2- 99.2) | 86.1 (75.7- 92.5) | 0.026 |
Maculopapular rash, < 25% of body surface | 100 | 92.9 |  |
Maculopapular rash, 25%-50% of body surface | 93.5 | 86.7 | Â |
Maculopapular rash, > 50% of body surface | 100 | 57.1 |  |
Lower GI and/or liver | 87.5 (63.9- 96.5) | 60.8 (40.7- 77.8) | 0.070 |
Diarrhea. > 500 but < 1000 mL/d | 100 | 81.8 |  |
Diarrhea > .1000 but < 1500 mL/d | 50 | 50 |  |
Diarrhea > .1500 mL/d | 0 | 0 |  |
bilirubin 2-3Â mg/dL | - | 40 | Â |
Bilirubin 3.1–6 mg/dL | 100 | 100 |  |
Graft source | |||
 PB | 97.1(89.9- 99.1) | 80.6 (69.1- 88.5) | 0.003 |
 BM | 100 (65.5–100) | 82.3 (55.8- 95.3) | 0.23 |
Donor source | |||
 Matched sibling | 100 (39.5–100) | 50.0 (13.9- 86.0) | 0.091 |
 Haploidentical or unrelated | 97.3 (90.6- 99.2) | 83.5 (73.4- 90.3) | 0.005 |
Center | |||
 Peking university | 98.2 (90.8- 99.7) | 83.0 (72.1- 90.2) | 0.005 |
 Others | 95.0 (73.0- 99.7) | 71.4 (42.0- 90.4) | 0.079 |